These findings indicate that, despite clinical and therapeutic progression, the gliogenesis-associated promoter landscape in IDH-wildtype GBM is conserved mainly, suggesting an epigenetic “core” maintained throughout tumor evolution. The gene discussed is IDH2; the disease is glioblastoma.